Chloroquine Tablet 200 mg (Hydroxychloroquine Sulfate)

Adult dose

1. Rheumatoid arthritis, juvenile rheumatoid arthritis, discoid and systemic lupus erythematosus, and photosensitive skin disorders Adults: The initial dose is 200～400mg daily; if administering 400mg, divide the dose. Once an effect is observed, reduce the dose to 200mg daily; if the response is inadequate, increase it to 400mg daily. The maintenance dose should be the minimum effective dose and must not exceed 6.5mg/kg/day. * Discontinue use if symptoms do not improve after 6 months of treatment for rheumatoid arthritis, juvenile rheumatoid arthritis, discoid and systemic lupus erythematosus. * For photosensitive disorders, administer only during periods of substantial exposure. 2. Malaria 1) Treatment Adults: For treatment of an acute condition, administer 800mg initially, followed by 400mg every 6∼8 hours for 3 additional doses, for a total of 2g over 2 days. For acute conditions caused by Plasmodium falciparum or Plasmodium vivax, a single 800mg dose may be administered. 2) Prevention Adults: Starting 2 weeks before exposure, administer 6mg/kg once weekly (usually 400mg once weekly).

Child dose

1. Rheumatoid arthritis, juvenile rheumatoid arthritis, discoid and systemic lupus erythematosus, and photosensitive skin disorders Children: The usual average daily dose is 200∼400mg. The maintenance dose should be the minimum effective dose, must not exceed 6.5mg/kg/day, and must not exceed the adult dose regardless of body weight. 2. Malaria 1) Treatment Children: Administer 10mg/kg of chloroquine initially, followed by 5mg/kg every 6-8 hours for 3 additional doses, for a total of 25mg/kg over 2 days. However, the adult dose must not be exceeded. 2) Prevention Children: Starting 2 weeks before exposure, administer 6mg/kg once weekly. For children weighing 30∼40kg or less, even 1 tablet (200mg) exceeds the appropriate dose; therefore, administration is not recommended.

This drug should not be used by certain patients. For example, those allergic to this drug or similar compounds, patients with eye problems, those taking medications that can cause visual impairment, children requiring long-term treatment, and women who are pregnant or breastfeeding should avoid taking this medication. Additionally, patients with certain conditions should use this medication with caution. For instance, those with a history of allergy to quinine, psoriasis, liver disease, kidney disease, severe gastrointestinal disorders, neurological disorders, blood disorders, or porphyria should take care when using this drug. This drug can cause various ocular adverse reactions. Visual disturbances or retinal abnormalities may occur, and while initially stopping the drug may result in recovery, ignoring symptoms can lead to permanent damage. Corneal edema or opacification may occur, causing blurred vision. Skin reactions such as rashes, hives, hair loss, and changes in pigmentation may also occur, and severe skin reactions can be rare, so careful monitoring of skin condition is necessary. Gastrointestinal disturbances can include nausea, diarrhea, loss of appetite, and abdominal pain, which typically resolve upon reducing or discontinuing the medication. Central nervous system side effects may include fatigue, headaches, hallucinations, drowsiness, and mood changes, with rare reports of severe symptoms such as psychosis or seizures. Muscle weakness or myopathy can occur, recovering upon discontinuation of the drug, though it may take time. Blood-related conditions may rarely cause anemia or leukopenia, necessitating periodic blood tests. Cardiac effects are possible, with risks of arrhythmia or cardiomyopathy, requiring careful monitoring of heart condition. Rarely reported liver function abnormalities or severe liver damage warrant liver function tests. Psychiatric side effects may include changes in mental state, depression, anxiety, and delusions; symptoms should be discussed with a healthcare provider immediately. Regular eye examinations are recommended while taking this medication to monitor eye health, especially for the elderly or patients with poor kidney function, who should be examined more frequently. Patients with severe liver or kidney disease should have their blood drug levels measured and adjust the dosage, and regular blood tests should be conducted to reduce the risk of bone marrow suppression. This drug has many interactions with other medications, so it is essential to inform healthcare professionals of any concurrent drugs, especially avoiding combinations with those that pose a risk of cardiac arrhythmia. It is safest for pregnant or breastfeeding women to avoid using this medication, and breastfeeding is recommended to be stopped while on this drug. In cases of overdose, serious side effects may occur, requiring immediate emergency treatment; treatments may involve vomiting or gastric lavage to remove the drug. This drug should be stored out of reach of children and should not be transferred to other containers.

Tremors in vision, retinal abnormalities, decreased sensitivity of the cornea, corneal opacity, pigmentation changes, visual disturbances, scotoma, color rings, glare, skin rash, urticaria, pigmentation changes in the skin and mucous membranes, hair discoloration, alopecia, vesicular rash, erythema multiforme, Stevens-Johnson syndrome, photosensitivity reaction, exfoliative dermatitis, Sweet's syndrome, severe skin adverse reactions, psoriatic flare, acute generalized pustular psoriasis, DRESS syndrome, nausea, diarrhea, loss of appetite, abdominal pain, upper abdominal cramps, vomiting, myasthenia, fatigue, neurogenic hearing loss, hallucinations, headache, drowsiness, restrictive neuro-excitability reactions, mood changes, nightmares, tinnitus, dizziness, hearing loss, unstable mood changes, psychosis, convulsions, skeletal muscle myopathy, neuromuscular disorder, perceptual changes, decreased reflexes, abnormal nerve conduction, aplastic anemia, agranulocytosis, leukopenia, thrombocytopenia, bone marrow suppression, QT prolongation, tachycardia due to electrolyte imbalances, ventricular tachycardia, cardiomyopathy, left ventricular hypertrophy, conduction disorders, abnormal liver function test results, fulminant hepatic failure, hepatocyte damage, cholestatic liver injury, acute hepatitis, mixed hepatocellular/cholestatic liver injury, fulminant liver failure, depression, hallucinations, anxiety, agitation, confusion, delusions, mania, sleep disorders, weight loss, lethargy

This medication should be stored in a tightly closed container to protect it from air and moisture. It is best to maintain storage temperatures between 1 and 30 degrees Celsius.

Appearance

White circular film-coated tablets

Package unit

30 tablets/bottle, 500 tablets/bottle (military supply: 100 tablets/bottle)